A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Inclusion Criteria:

   - Histologically or cytologically confirmed diagnosis of metastatic NSCLC according to
   the 7th edition of the AJCC Cancer Staging Manual. In addition, the NSCLC must harbor
   an ALK rearrangement, as assessed using the FDA approved Vysis ALK Break Apart FISH
   Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity
   criteria). If documentation of ALK rearrangement as described above was not locally
   available, a test to confirm ALK rearrangement was to be performed by a Novartis
   designated central laboratory. Patients had to wait for the central laboratory result
   of the ALK rearrangement status before initiating treatment with ceritinib

   - At least one extracranial measurable lesion as defined by RECIST 1.1. A previously
   irradiated site lesion could only be counted as a target lesion if there was clear
   sign of progression since the irradiation.

   - Patients could or could not have neurological symptoms but must have been able to
   swallow and retain oral medication.

   - Patients had to be neurologically stable within at least 1 week prior to the first
   dose of study drug.

   - Patients could have received prior chemotherapy, crizotinib (other ALK inhibitors were
   not allowed), biologic therapy or other investigational agents.

   - Patients must have recovered from all toxicities related to prior anticancer therapies
   to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia were allowed to enter
   the study.

   - Patient had life expectancy ≥ 6 weeks.

   - Patient had a WHO performance status 0-2.

Patients in Arm 1 to 4 had to also meet the following inclusion criteria:

- Patients had to have active brain metastases from NSCLC, confirmed by Gadolinium-enhanced
MRI without concomitant leptomeningeal carcinomatosis. Dose of steroids had to be stable
for 5 days before the baseline brain MRI.

Patients in Arm 5 had to also meet the following inclusion criteria:

- Patients must have been diagnosed with leptomeningeal carcinomatosis.

Exclusion Criteria:

   - Patients who needed whole brain radiation to control the brain metastases. Patients
   were not eligible unless treated brain lesions were progressive or new brain lesions
   were observed since the post whole brain radiation therapy MRI.

   - Planning of any brain local treatment (including but not limited to surgery,
   stereotactic radiosurgery, whole brain radiation, intrathecal chemotherapy) following
   the administration of the first dose of study drug.

   - Patient with a concurrent malignancy or history of a malignant disease other than
   NSCLC that had been diagnosed and/or required therapy within the past 3 years.
   Exceptions to this exclusion included the following: completely resected basal cell
   and squamous cell skin cancers, and completely resected carcinoma in situ of any type.

   - Patient had impairment of GI function or GI disease that could significantly alter the
   absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting,
   diarrhea, or malabsorption syndrome).

   - Patient was receiving unstable or increasing doses of corticosteroids.

   - Patient had other severe, acute, or chronic medical conditions including uncontrolled
   diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the
   opinion of the investigator could increase the risk associated with study
   participation, or that could interfere with the interpretation of study results.